Bakker Juliet Tammenoms
CIK 1431159 · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.62B
Companies
15
Total Filings
57
Lifetime Open-Market Net
$193.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RXST | Director | 86,731 | $6.01 | $521.3K | -$13.82M | 18 | 2026-06-18 |
| CBLL | Director | 2,498,394 | $17.69 | $44.20M | $4.03M | 3 | 2026-06-04 |
| VERA | 10%+ Owner | 3,429,927 | $32.10 | $110.10M | $60.00M | 1 | 2023-02-08 |
| Sierra Oncology, Inc. (SRRA) Delisted | 10%+ Owner | 175,000 | $54.99 | $9.62M | $28.35M | 3 | 2022-02-02 |
| RPID | 10%+ Owner | 150,000 | $2.13 | $319.5K | $18.00M | 1 | 2021-07-20 |
| Eargo, Inc. (EAR) Delisted | Director | 96,286 | $2.57 | $247.5K | $4.20M | 4 | 2021-05-19 |
| Tourmaline Bio, Inc. (TALS) Delisted | 10%+ Owner | 322,078 | $27.20 | $8.76M | $15.98M | 1 | 2021-05-11 |
| Axonics, Inc. (AXNX) Delisted | Director | 1,958,833 | $70.98 | $139.04M | $7.51M | 9 | 2020-09-22 |
| Molecular Templates, Inc. (MTEM) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $29.85M | 2 | 2020-09-01 |
| Venus Concept Inc. (HAIR) Delisted | Director | 231,772 | — | — | $0 | 1 | 2019-11-07 |
| Tricida, Inc. (TCDA) Delisted | 10%+ Owner | 3,019,734 | $0.11 | $326.1K | $10.00M | 1 | 2018-07-02 |
| Aptinyx Inc. (APTX) Delisted | 10%+ Owner | 3,190,079 | $0.06 | $194.6K | $7.20M | 1 | 2018-06-26 |
| COLL | 10%+ Owner | 6,029,785 | $35.39 | $213.39M | $12.30M | 2 | 2018-02-26 |
| CORT | Director | 10,874,259 | $114.49 | $1.24B | $11.70M | 4 | 2016-12-19 |
| ESPR | 10%+ Owner | 1,883,769 | $3.18 | $5.99M | -$1.55M | 2 | 2014-10-14 |
Recent Filings · Page 4 of 6
57 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-05-11 | Tourmaline Bio, Inc. (TALS) Delisted | Mixed | +12,883,100 | $15.98M | EDGAR |
| 2021-04-15 | Eargo, Inc. (EAR) Delisted | Other (J) | −994,988 | $0 | EDGAR |
| 2020-10-22 | Eargo, Inc. (EAR) Delisted | Mixed | +3,918,691 | $4.20M | EDGAR |
| 2020-10-19 | Eargo, Inc. (EAR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-09-22 | Axonics, Inc. (AXNX) Delisted | Sell (S) | −9,167 | -$391.1K | EDGAR |
| 2020-09-01 | Molecular Templates, Inc. (MTEM) Delisted | Sell (S) | −13,984 | -$150.3K | EDGAR |
| 2020-08-26 | Axonics, Inc. (AXNX) Delisted | Grant (A) | +3,500 | $0 | EDGAR |
| 2020-08-18 | Axonics, Inc. (AXNX) Delisted | Sell (S) | −2,393 | -$103.4K | EDGAR |
| 2020-08-12 | Axonics, Inc. (AXNX) Delisted | Other (J) | −974,581 | $0 | EDGAR |
| 2020-01-31 | Sierra Oncology, Inc. (SRRA) Delisted | Conv (C) | +5,909,280 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.